Dr. John Heymach Jr, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Stanford University

  Medical School, 1998

• Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing, 2021-05-10

• Spatial PD-L1, immune-cell microenvironment and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort, 2023-01-03

• Long-Term Outcomes of Salvage Stereotactic Ablation Radiotherapy for Isolated Lung Recurrence of Non-Small-Cell Lung Cancer: A Phase II Clinical Trial, 2017-03-01

• Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities, 2021-01-21

• Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer, 2019-01-29

• Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Outcomes With Salvage Treatment for Recurrence After Radiotherapy for Lung Cancer, 2018-08-24

• Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer, 2017-02-15

• KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib, 2015-11-17

• Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1, 2012-09-06

• A Bayesian Adaptive-Randomization Trial of Passive-Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer, 2018-01-02

• Stereotactic Ablative Radiotherapy is a Highly Effective Treatment for Early Stage Non-Small Cell Lung Cancer in Elderly Patients, 2016-12-21

• Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion, 2012-07-17

• Joint prognostic effect of obesity and chronic systemic inflammation in metastatic colorectal cancer, 2015-05-14

• LKB1 mutations in NSCLC are associated with KEAP1/NRF2-dependent radiotherapy resistance targetable by glutaminase inhibition, 2020-12-15

• Inhibition of nonsense-mediated decay rescues p53ß/? isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers, 2021-09-03

• Identification ofKRASG12CMutations in Circulating Tumor DNA in Patients With Cancer, 2022-07-21

• Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma, 2022-03-21

• Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer, 2023-04-25

• Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas, 2021-01-29

• Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma, 2016-02-05

• Netie: Inferring the evolution of neoantigen-T cell interactions in tumors, 2022-10-27

• Targeted Therapies for Lung Cancer Clinical Experience and Novel Agents, 2012-06-06

• A pan-cancer proteomic perspective on The Cancer Genome Atlas, 2014-05-29

• Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer., 2019-08-27

• Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer, 2021-11-17

• Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression, 2014-10-28

• Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID), 2023-05-26

• Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment, 2022-08-10

• Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial, 2023-03-16

• Radiation followed by OX40 stimulation drives local and abscopal antitumor effects in an anti-PD1-resistant lung tumor model, 2018-05-21

• Circulating Biomarkers of Response to Sunitinib in Gastroenteropancreatic Neuroendocrine Tumors Current Data and Clinical Outlook, 2012-06-01

• Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma, 2021-05-12

• Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients, 2016-06-01

• Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis, 2023-10-01

• An IRAK1-PIN1 Signalling Axis Drives Intrinsic Tumour Resistance to Radiation Therapy, 2019-01-21

• STK11/LKB1Mutations and PD-1 Inhibitor Resistance inKRAS-Mutant Lung Adenocarcinoma, 2018-05-17

• Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer, 2020-01-20

• Taxane-Platin Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors, 2017-05-23

• miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by TargetingFlt1/VEGFR1, 2010-11-29

• Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma, 2022-05-11

• Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target inLKB1Mutant Lung Cancer, 2013-05-28

• A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non-Small Cell Lung Cancer, 2014-06-26

• Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma, 2022-07-17

• CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells, 2017-05-24

• Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer, 2023-06-06

• LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence inKRAS-mutant lung adenocarcinoma, 2019-04-30

• Multifactorial deep learning reveals pan-cancer genomic tumor clusters with distinct immunogenomic landscape and response to immunotherapy, 2020-01-07

• Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy, 2014-03-13

• Prognostic Factors as a Function of Disease-Free Interval after Definitive (Chemo)radiation for Non-Small Cell Lung Cancer using Conditional Survival Analysis, 2015-09-29

• Altered regulation of HIF-1a in naive- and drug-resistant EGFR mutant NSCLC: implications for a VEGF-dependent phenotype, 2020-12-09

• Toxicity and Survival after Intensity-Modulated Proton Therapy (IMPT) versus Passive Scattering Proton Therapy (PSPT) for Non-Small Cell Lung Cancer, 2020-10-22

• Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice, 2019-07-09

• Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer, 2016-04-07

• Prognostic Impact of Radiation Therapy to the Primary Tumor in Patients With Non-small Cell Lung Cancer and Oligometastasis at Diagnosis, 2012-04-13

• The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma, 2019-11-06

• Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus, 2012-06-04

• Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with beta blockers, 2017-11-08

• A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer, 2020-03-19

• Di fferential S ensitivity A nalysis for R esistant M alignancies (DISARM) identifies common candidate therapies across platinum-resistant cancers, 2018-09-26

• Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells, 2017-03-02

• Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study, 2016-10-24

• ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer, 2021-05-17

• Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy, 2023-01-04

• Molecular landscape ofBRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations, 2020-06-13

• Co-occurring genomic alterations in non-small cell lung cancer biology and therapy, 2019-08-12

• Single-Cell Expression Landscape of SARS-CoV-2 ReceptorACE2and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients, 2021-03-12

• The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer, 2013-10-15

• Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity, 2020-11-04

• Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches, 2018-06-06

• ActivatingNOTCH1mutations define a distinct subgroup of adenoid cystic carcinoma patients with poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors, 2016-11-21

• Variants with low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing, 2017-11-27

• Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy, 2017-11-02

• Phase I/II Trial of Immunotherapy with Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early trial report, 2020-03-04

• Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer, 2018-11-26

• Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC, 2018-09-18

• A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components, 2020-09-02

• STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment, 2016-02-01

• Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy, 2013-02-19

• Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer, 2017-05-05

• PD-1 blockade prevents the development and progression of carcinogen-induced oral premalignant lesions, 2017-10-10

• Can the Lung Cancer Pie Be Divided into Angiogenic Slices?, 2015-07-31

• Comprehensive T cell repertoire characterization of non-small cell lung cancer, 2020-01-30

• Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer, 2014-11-18

• Characterization of Human Cancer Cell Lines by Reverse-Phase Protein Arrays, 2017-02-13

• Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer, 2022-01-23

• 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer, 2020-04-16

• Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20-selective Kinase Inhibitor in Non-small Cell Lung Cancer, 2018-04-23

• TGFß1Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy, 2013-06-19

• Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia, 2023-01-31

• CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma, 2012-11-30

• Strategies for combining immunotherapy with radiation for anticancer therapy, 2015-08-27

• Effect of Low-fat Diets on Plasma Levels of NF?B-regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer, 2011-07-15

• Profiles of Brain Metastases: Prioritization of Therapeutic Targets, 2018-10-09

• Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition, 2014-12-08

• 7-year Follow-Up Outcomes after Stereotactic Ablation Radiotherapy for Stage I NSCLC: Results of a Phase ? Clinical Trial, 2017-03-27

• STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype, 2020-02-15

• Antibody-drug conjugates in lung cancer: dawn of a new era?, 2023-01-11

• Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma, 2019-07-05

• Focal Adhesion Kinase regulates the DNA damage response and its inhibition radiosensitizes mutantKRASlung cancer, 2016-05-24

• Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T cell Therapy, 2018-04-05

• Co-occurring genomic alterations define major subsets ofKRAS -mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities, 2015-06-11

• Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab Driver Oncogene Variations and Patients With Locally Advanced NSCLC, 2022-06-06

• Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies, 2017-09-01

• Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus inKIF5B-RETre-arranged Non-Small Cell Lung Cancer with brain metastases, 2015-04-22

• AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers, 2016-09-26

• Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer withT790Mmutations, 2016-06-30

• Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S., 2016-05-27

• A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial to mesenchymal transition, 2015-09-29

• The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA, 2012-03-09

• Enhanced vulnerability of LKB1-deficient NSCLC to disruption of ATP pools and redox homeostasis by 8-Cl-Ado, 2021-10-15

• CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib, 2017-05-10

• The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer, 2017-05-30

• The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics, 2021-12-06

• BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer, 2017-11-07

• Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer, 2021-08-19

• Stereotactic Ablative Radiotherapy for Operable Stage I Non-Small Cell Lung Cancer: Long-Term Results of the Single-Arm STARS Prospective Trial, 2021-09-13

• Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets, 2020-11-10

• Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021-02-18

• An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance, 2012-10-22

• Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC, 2022-06-01

• Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer, 2020-02-17

• Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells, 2015-12-09

• Bevacizumab beyond disease progression for advanced NSCLC: Does persistence have its rewards?, 2016-02-01

• Genomic heterogeneity of multiple synchronous lung cancer, 2016-10-21

• Predictive biomarkers in precision medicine and drug development against lung cancer, 2015-07-02

• 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition, 2015-08-27

• Concurrent use of aspirin with osimertinib is associated with improved survival in advancedEGFR-mutant non-small cell lung cancer, 2020-09-09

• AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors, 2020-11-10

• Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer, 2019-02-18

• Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer, 2015-11-23

• Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features, 2021-05-11

• An Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective Randomized Control Trials, 2016-11-27

• Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer, 2017-05-23

• A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis and Metastasis in Aneuploid Cancers, 2020-12-04

• Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivatingBRAFmutations, 2015-11-23

• A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma, 2014-09-05

• Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer, 2023-02-08

• Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer, 2017-07-11

• Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer, 2019-09-21

• High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer, 2019-12-16

• BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study, 2023-02-18

• Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells?, 2012-02-22

• Quantitative proteomic analysis of optimal cutting temperature (OCT) embedded core-needle biopsy of lung cancer, 2017-07-27

• Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer, 2018-08-06

• Inhibition of thioredoxin/thioredoxin reductase induces synthetic lethality in lung cancers with compromised glutathione homeostasis, 2018-11-06

• Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy, 2019-09-04

• Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses, 2019-10-28

• Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer, 2020-10-21